Clinical Trial Update: CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) [Phase 1]

View source ↗

Summary

CERo Therapeutics is conducting a Phase 1 trial of CER-1236 for acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis; the study is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelofibrosis

Drugs mentioned

• CER-1236

Snippet

Sponsor: CERo Therapeutics Holdings, Inc. | Conditions: AML, Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING